193 related articles for article (PubMed ID: 32801003)
1. Permuted 2,4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells.
Tilekar K; Upadhyay N; Schweipert M; Hess JD; Macias LH; Mrowka P; Meyer-Almes FJ; Aguilera RJ; Iancu CV; Choe JY; Ramaa CS
Eur J Pharm Sci; 2020 Nov; 154():105512. PubMed ID: 32801003
[TBL] [Abstract][Full Text] [Related]
2. Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential.
Tilekar K; Upadhyay N; Hess JD; Macias LH; Mrowka P; Aguilera RJ; Meyer-Almes FJ; Iancu CV; Choe JY; Ramaa CS
Eur J Med Chem; 2020 Sep; 202():112603. PubMed ID: 32634629
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation.
Upadhyay N; Tilekar K; Jänsch N; Schweipert M; Hess JD; Henze Macias L; Mrowka P; Aguilera RJ; Choe JY; Meyer-Almes FJ; Ramaa CS
Bioorg Chem; 2020 Jul; 100():103934. PubMed ID: 32446120
[TBL] [Abstract][Full Text] [Related]
4. GLUT3 inhibitor discovery through in silico ligand screening and in vivo validation in eukaryotic expression systems.
Iancu CV; Bocci G; Ishtikhar M; Khamrai M; Oreb M; Oprea TI; Choe JY
Sci Rep; 2022 Jan; 12(1):1429. PubMed ID: 35082341
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel class of glucose transporter inhibitors.
Wang D; Chu PC; Yang CN; Yan R; Chuang YC; Kulp SK; Chen CS
J Med Chem; 2012 Apr; 55(8):3827-36. PubMed ID: 22468970
[TBL] [Abstract][Full Text] [Related]
6. Hexose transporter mRNAs for GLUT4, GLUT5, and GLUT12 predominate in human muscle.
Stuart CA; Yin D; Howell ME; Dykes RJ; Laffan JJ; Ferrando AA
Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E1067-73. PubMed ID: 16803853
[TBL] [Abstract][Full Text] [Related]
7. Towards Selective Binding to the GLUT5 Transporter: Synthesis, Molecular Dynamics and In Vitro Evaluation of Novel C-3-Modified 2,5-Anhydro-D-mannitol Analogs.
Rana N; Aziz MA; Oraby AK; Wuest M; Dufour J; Abouzid KAM; Wuest F; West FG
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456662
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a specific inhibitor of human GLUT5 by virtual screening and in vitro transport evaluation.
George Thompson AM; Ursu O; Babkin P; Iancu CV; Whang A; Oprea TI; Choe JY
Sci Rep; 2016 Apr; 6():24240. PubMed ID: 27074918
[TBL] [Abstract][Full Text] [Related]
9. Molecular Imaging of GLUT1 and GLUT5 in Breast Cancer: A Multitracer Positron Emission Tomography Imaging Study in Mice.
Wuest M; Hamann I; Bouvet V; Glubrecht D; Marshall A; Trayner B; Soueidan OM; Krys D; Wagner M; Cheeseman C; West F; Wuest F
Mol Pharmacol; 2018 Feb; 93(2):79-89. PubMed ID: 29142019
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines.
Tilekar K; Upadhyay N; Jänsch N; Schweipert M; Mrowka P; Meyer-Almes FJ; Ramaa CS
Bioorg Chem; 2020 Jan; 95():103522. PubMed ID: 31901516
[TBL] [Abstract][Full Text] [Related]
11. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment.
Barron CC; Bilan PJ; Tsakiridis T; Tsiani E
Metabolism; 2016 Feb; 65(2):124-39. PubMed ID: 26773935
[TBL] [Abstract][Full Text] [Related]
12. A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism.
Shriwas P; Roberts D; Li Y; Wang L; Qian Y; Bergmeier S; Hines J; Adhicary S; Nielsen C; Chen X
Cancer Metab; 2021 Mar; 9(1):14. PubMed ID: 33771231
[TBL] [Abstract][Full Text] [Related]
13. Expression and function of hexose transporters GLUT1, GLUT2, and GLUT5 in breast cancer-effects of hypoxia.
Hamann I; Krys D; Glubrecht D; Bouvet V; Marshall A; Vos L; Mackey JR; Wuest M; Wuest F
FASEB J; 2018 Sep; 32(9):5104-5118. PubMed ID: 29913554
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel GLUT1 inhibitor with in vitro and in vivo anti-tumor activity.
Chen X; Zhao Y; He C; Gao G; Li J; Qiu L; Wang X; Gao Y; Qi Y; Sun K; Du J
Int J Biol Macromol; 2022 Sep; 216():768-778. PubMed ID: 35878663
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human GLUT1 and GLUT5 by plant carbohydrate products; insights into transport specificity.
George Thompson AM; Iancu CV; Nguyen TT; Kim D; Choe JY
Sci Rep; 2015 Aug; 5():12804. PubMed ID: 26306809
[TBL] [Abstract][Full Text] [Related]
16. WZB117 (2-Fluoro-6-(m-hydroxybenzoyloxy) Phenyl m-Hydroxybenzoate) Inhibits GLUT1-mediated Sugar Transport by Binding Reversibly at the Exofacial Sugar Binding Site.
Ojelabi OA; Lloyd KP; Simon AH; De Zutter JK; Carruthers A
J Biol Chem; 2016 Dec; 291(52):26762-26772. PubMed ID: 27836974
[TBL] [Abstract][Full Text] [Related]
17. Ligand-based design of GLUT inhibitors as potential antitumor agents.
Almahmoud S; Jin W; Geng L; Wang J; Wang X; Vennerstrom JL; Zhong HA
Bioorg Med Chem; 2020 Apr; 28(7):115395. PubMed ID: 32113844
[TBL] [Abstract][Full Text] [Related]
18. Isoform-selective inhibition of facilitative glucose transporters: elucidation of the molecular mechanism of HIV protease inhibitor binding.
Hresko RC; Kraft TE; Tzekov A; Wildman SA; Hruz PW
J Biol Chem; 2014 Jun; 289(23):16100-13. PubMed ID: 24706759
[TBL] [Abstract][Full Text] [Related]
19. GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle.
Aerni-Flessner L; Abi-Jaoude M; Koenig A; Payne M; Hruz PW
Cardiovasc Diabetol; 2012 Jun; 11():63. PubMed ID: 22681646
[TBL] [Abstract][Full Text] [Related]
20. In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.
Mishra RK; Wei C; Hresko RC; Bajpai R; Heitmeier M; Matulis SM; Nooka AK; Rosen ST; Hruz PW; Schiltz GE; Shanmugam M
J Biol Chem; 2015 Jun; 290(23):14441-53. PubMed ID: 25847249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
